Atomo Wins A$630,000 Order for Government-Backed HIV Self-Testing Program

The latest update is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).

Atomo Diagnostics has secured a material purchase order worth approximately A$630,000 from the National Association of People with HIV Australia to supply HIV self-tests for the national free-to-user HIV self-testing mail-out program. The government-backed initiative, supported by platforms such as Grindr, aims to boost testing rates among high-risk groups by providing discreet, convenient at-home testing, reinforcing Atomo’s position in the HIV diagnostics space and underpinning its revenue with continued public funding for key HIV self-test programs.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies patented, integrated rapid diagnostic test devices to the global diagnostics market. Its products are designed to simplify testing procedures, enhance usability and improve reliability for rapid point-of-care and at-home testing, with commercialised solutions and supply agreements covering infectious diseases including sexual health and female health across international markets.

Average Trading Volume: 1,286,976

Technical Sentiment Signal: Buy

Current Market Cap: A$34.03M

For an in-depth examination of AT1 stock, go to TipRanks’ Overview page.